Want to see IN:CONCORDBIO full AI Analyst Report?
Concord Biotech Ltd. (CONCORDBIO) Stock Statistics & Valuation Metrics
Total Valuation
Concord Biotech Ltd. has a market cap or net worth of INR 130.28B. The enterprise value is INR 139.20B.
- Market Cap
- INR 130.28B
- Enterprise Value
- INR 139.20B
Share Statistics
Concord Biotech Ltd. has 104,616,200 shares outstanding. The number of shares has decreased by -2.65% in one year.
- Shares Outstanding
- 104,616,200
- Owned by Insiders
- ―
- Owned by Institutions
- ―
Financial Efficiency
Concord Biotech Ltd.’s return on equity (ROE) is 0.13 and return on invested capital (ROIC) is 10.66%.
- Return on Equity (ROE)
- 0.13
- Return on Assets (ROA)
- 0.12
- Return on Invested Capital (ROIC)
- 10.66%
- Return on Capital Employed (ROCE)
- 0.14
- Revenue Per Employee
- 6.50M
- Profits Per Employee
- 1.61M
- Employee Count
- 1,624
- Asset Turnover
- 0.47
- Inventory Turnover
- 1.88
Valuation Ratios
The current PE Ratio of Concord Biotech Ltd. is 46.20. Concord Biotech Ltd.’s PEG ratio is -3.61.
- PE Ratio
- 46.20
- PS Ratio
- 11.13
- PB Ratio
- 6.28
- Price to FCF
- 133.53
- Price to Operating Cash Flow
- 86.25
- PEG Ratio
- -3.61
Income Statement
In the last 12 months, Concord Biotech Ltd. had revenue of 10.55B and earned 2.61B in profits. Earnings per share was 24.78.
- Revenue
- 10.55B
- Gross Profit
- 4.42B
- Operating Income
- 2.93B
- Pretax Income
- 3.45B
- Net Income
- 2.61B
- EBITDA
- 4.19B
- Earnings Per Share (EPS)
- 24.78
Cash Flow
In the last 12 months, operating cash flow was 1.51B and capital expenditures -534.99M, giving a free cash flow of 975.85M billion.
- Operating Cash Flow
- 1.51B
- Free Cash Flow
- 975.85M
- Free Cash Flow per Share
- 9.33
Dividends & Yields
Concord Biotech Ltd. pays an annual dividend of INR 7.55, resulting in a dividend yield of 0.61%
- Dividend Per Share
- INR 7.55
- Dividend Yield
- 0.61%
- Payout Ratio
- 72.71%
- Free Cash Flow Yield
- 0.75%
- Earnings Yield
- 2.17%
Stock Price Statistics
- Beta
- 0.98
- 52-Week Price Change
- -14.28%
- 50-Day Moving Average
- 1414.90
- 200-Day Moving Average
- 1256.85
- Relative Strength Index (RSI)
- 39.91
- Average Volume (3m)
- 47.82K
Important Dates
Concord Biotech Ltd. upcoming earnings date is Feb 18, 2027, TBA (Not Confirmed).
- Last Earnings Date
- Oct 27, 2026
- Next Earnings Date
- Feb 18, 2027
- Ex-Dividend Date
- Jul 24, 2026
Financial Position
Concord Biotech Ltd. as a current ratio of 7.39, with Debt / Equity ratio of 0.11%
- Current Ratio
- 7.39
- Quick Ratio
- 5.46
- Debt to Market Cap
- 0.00
- Net Debt to EBITDA
- -0.03
- Interest Coverage Ratio
- 1034.40
Taxes
In the past 12 months, Concord Biotech Ltd. has paid 854.18M in taxes.
- Income Tax
- 854.18M
- Effective Tax Rate
- 0.25
Enterprise Valuation
Concord Biotech Ltd. EV to EBITDA ratio is 30.62, with an EV/FCF ratio of 133.48.
- EV to Sales
- 11.13
- EV to EBITDA
- 30.62
- EV to Free Cash Flow
- 133.48
- EV to Operating Cash Flow
- 86.21
Balance Sheet
Concord Biotech Ltd. has INR 4.32B in cash and marketable securities with INR 0.00 in debt, giving a net cash position of INR 4.32B billion.
- Cash & Marketable Securities
- INR 4.32B
- Total Debt
- INR 0.00
- Net Cash
- INR 4.32B
- Net Cash Per Share
- INR 41.28
- Tangible Book Value Per Share
- INR 192.62
Margins
Gross margin is 42.39%, with operating margin of 28.15%, and net profit margin of 24.13%.
- Gross Margin
- 42.39%
- Operating Margin
- 28.15%
- Pretax Margin
- 31.96%
- Net Profit Margin
- 24.13%
- EBITDA Margin
- 36.35%
- EBIT Margin
- 29.96%
Analyst Forecast
The average price target for Concord Biotech Ltd. is ―, which is 11.43% higher than the current price. The consensus rating is ―
- Price Target
- ―
- Price Target Upside
- ―
- Analyst Consensus
- ―
- Analyst Count
- ―
- Revenue Growth Forecast
- 4.02%
- EPS Growth Forecast
- -12.81%
Scores
- Smart Score
- ―
- AI Score
- 76